Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported. This study aims to investigate the efficacy and safety of combination therapy compared with furmonertinib monotherapy in advanced EGFR mutant NSCLC with uncleared circulating tumor cell DNA.

Trial Details

NCT ID
NCT05334277
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Furmonertinib
  • Furmonertinib/Pemetrexed/Carboplatin
  • Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
Locations (sample)
  • Changchun, China|43.88,125.32278
  • Chengdu, China|30.66667,104.06667
  • Dongguan, China|23.01797,113.74866
  • Dongyang, China|29.26778,120.22528
  • Foshan, China|23.02677,113.13148

Key Eligibility Criteria

  • Provide informed consent prior to any study specific procedures;
  • at least 18 years of age;
  • ECOG PS of 0 to 1 at screening with no clinically significant deterioration in the previous 2 weeks, life expectancy ≥12 weeks;
  • Pathologically confirmed non-squamous Non-Small Cell Lung Cancer (NSCLC);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →